|Bid||10.89 x 1400|
|Ask||11.00 x 1000|
|Day's range||10.18 - 11.76|
|52-week range||10.18 - 41.93|
|Beta (5Y monthly)||2.29|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.25|
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...